Why surgery won the SYNTAX trial and why it matters

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiac Surgery

Background:

• The Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) trial analyzed causes of death.
• A key focus was comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in higher-risk patients.

Discussion:

• Cardiac death due to myocardial infarction was notably higher (10x) with PCI versus CABG in higher-risk cohorts.
• CABG demonstrated a significant survival advantage over PCI in intermediate and high SYNTAX score groups with 3-vessel disease.
• Surgery also showed a statistically significant and time-increasing benefit in high SYNTAX score patients with left main disease.

Key Insights:

• Coronary artery bypass grafting is superior to percutaneous coronary intervention in preventing cardiac death in higher-risk patients with complex coronary artery disease.
• The survival benefit of CABG over PCI increases over time, particularly in patients with high SYNTAX scores and multi-vessel or left main disease.
• Transparent communication of these findings to patients is crucial for informed decision-making regarding treatment options.

Outlook:

• Further long-term follow-up of SYNTAX trial data will continue to refine understanding of PCI versus CABG outcomes.
• Enhanced risk stratification tools may further guide optimal revascularization strategies.
• Clinical practice guidelines should emphasize the long-term benefits of CABG in specific high-risk patient populations.